Serous Tubal Intraepithelial Carcinoma After Neoadjuvant Chemotherapy: A Report of 2 Cases.
Journal
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
ISSN: 1538-7151
Titre abrégé: Int J Gynecol Pathol
Pays: United States
ID NLM: 8214845
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
aheadofprint
Résumé
Serous tubal intraepithelial carcinoma (STIC) is regarded as the origin of most high-grade serous carcinomas (HGSC). After a diagnosis of isolated STIC, risk of developing HGSC is substantial. Since surveillance cannot detect HGSC in time to cure the disease, there is no consensus on the optimal treatment after a diagnosis of isolated STIC, but chemotherapy is considered one of the possible strategies. In this case report, we describe 2 women with advanced-stage HGSC treated with 3 cycles of neoadjuvant chemotherapy followed by interval debulking surgery. In both women, histopathological examination showed a complete histopathological tumor response, but a vital STIC was found in both cases. The 2 cases presented here indicate that STICs may not respond to chemotherapy. Further research focused on the underlying biology and chemosensitivity of STIC, as well as the effectiveness of treatment to prevent HGSC in case of isolated STIC, is needed.
Identifiants
pubmed: 39173127
doi: 10.1097/PGP.0000000000001045
pii: 00004347-990000000-00171
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
L.C.L.T.v.K.: Grants from Amgen, AstraZeneca, Bayer, Janssen-Cilag, Merck, NanoString, Roche, Servier. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Janssen, NanoString, Novartis, Pfizer, and Roche. Support provided for attending meetings and/or travel from Roche, NanoString, and ThermoFisher. Advisory Board from Cyclomics, Janssen-Cilag, LOGEX, Merck, Menarini, Protyon, Roche. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from EORTC Melanoma Group, Commission Personalized Medicine – Belgium. Stock from Cyclomics. Receipt of equipment, materials, drugs, medical writing, gifts, or other services from LOGEX, Lynxcare, and NanoString. All are not related to this manuscript. J.B.: Grants from Dutch Cancer Society, AstraZeneca. All are not related to this manuscript. M.J.: Advisory board of Pierre Fabre. All are not related to this manuscript. The remaining authors declare no conflicts of interest.
Références
Steenbeek MP, van Bommel MHD, Bulten J, et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: A systematic review and individual patient data meta-analysis. J Clin Oncol 2022;40:1879–1891.
Shih IM, Wang Y, Wang TL. The origin of ovarian cancer species and precancerous landscape. Am J Pathol 2021;191:26–39.
Colon E, Carlson JW. Evaluation of the fallopian tubes after neoadjuvant chemotherapy: persistence of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 2014;33:463–469.
Nishimura R, Osako T, Okumura Y, et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 2010;17:269–275.
Conner JR, Meserve E, Pizer E, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol 2014;132:280–286.
Powell CB, Swisher EM, Cass I, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 2013;129:364–371.
Rush SK, Swisher EM, Garcia RL, et al. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience. Gynecol Oncol 2020;157:514–520.
Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230–236.